Skip to content

The investigation of anti-fibrosis effect of verapamil on patients with urethral stricture

The investigation of anti-fibrosis effect of verapamil on patients with urethral stricture

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011533
Enrollment
Unknown
Registered
2017-05-31
Start date
2017-08-01
Completion date
Unknown
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urethral Stricture

Interventions

experimental group:undertake 2ml injection of verapamil around the anastomosis site of urethra intraoperatively and postoperatively
control group:only receive the transperineal anastomosis surgery for urethral stricture

Sponsors

Xiangya Hospital of Centre South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 77 Years

Inclusion criteria

Inclusion criteria: Male adults, Diganosed as post-traumatic urethral stricture, Met with the operation indix of transperineal anastomosis of urethral stricture, sgined the informed consent.

Exclusion criteria

Exclusion criteria: Female patients or minor adolescents,Allergic to verapamil, With low blood pressure or heart diseases, Urethral stricture caused by nonspecific inflammation or congenital factor, With other diseases that can lead to dysuria (such as BPH and neurogenic bladder), With cicatricial diathesis, Refused to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
palpation of urethral scar range;measuring the narrowest inner diameter of urethral lumen;measuring the urethral scar tissue range;maxium urine flow rate (Qmax);measuring the urethral scar tissue range;

Countries

Chian

Contacts

Public ContactZheng-Yan Tang

Xiangya hospital of Central South University

doczhengyantang@163.com+86 13507318268

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026